Massey researcher receives $2 million grant to improve melanoma treatment
VCU Massey Cancer Center researcher Jason Reed, Ph.D., has been awarded a roughly $2 million grant with a collaborator at the University of California, Los Angeles, to develop a new method to rapidly determine how a cancerous tumor responds to a battery of candidate therapies and then to pick the agents that are most effective for treating the patient’s particular disease.
Immunotherapy: Unlocking New Ways to Fight Cancer
Learning of a cancer diagnosis has commonly brought with it not only fears for one’s health and one’s life, but the knowledge that the path to successful treatment was by no means easy or risk free. Most chemotherapy and radiation treatments come at a high expense to the patient’s body—harming healthy cells right along with malicious cancer cells and putting patients at risk for other cancers or even other disease or health problems. While in the best circumstances the end result is permanent elimination of cancer, in too many instances a few cancer cells survive and lead to relapse. Immunotherapy offers the potential to allow the body to kill the remaining resistant tumor cells.
A bright future made possible
This time of year, hundreds of area high school seniors don caps and gowns and look forward to life after high school. For Aaron Kurz, it’s an especially momentous occasion because it was one that his parents once feared he may never live to see.
Visiting scholar researches palliative and end-of-life care at VCU
Jane Seymour, Ph.D., professor of palliative and end-of-life studies in the School of Nursing, Midwifery and Physiotherapy at the University of Nottingham, traveled to Virginia Commonwealth University from the United Kingdom in April to begin her summer-long appointment as a VCU Global Visiting Scholar.
Massey physician co-led landmark research that establishes a new standard of care for young women with hormone-sensitive breast cancer
VCU Massey Cancer Center physician-researcher Charles Geyer, M.D., co-authored practice-changing, international research on breast cancer that this weekend was presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published online in the New England Journal of Medicine. This landmark study is the first to demonstrate that taking exemestane while blocking ovarian function reduces cancer recurrence in young women with hormone-receptive breast cancer.